摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7,8-二甲氧基-1,3,4,5-四氢苯并氮杂卓-2-酮 | 20925-64-8

中文名称
7,8-二甲氧基-1,3,4,5-四氢苯并氮杂卓-2-酮
中文别名
7,8-二甲氧基-1,3-二氢-2H-苯并氮杂卓
英文名称
7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one
英文别名
7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one;7,8-dimethoxy-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepine;7,8-Dimethoxy-1,3,4,5-tetrahydrobenzo[D]azepin-2-one;7,8-dimethoxy-1,2,3,5-tetrahydro-3-benzazepin-4-one
7,8-二甲氧基-1,3,4,5-四氢苯并氮杂卓-2-酮化学式
CAS
20925-64-8
化学式
C12H15NO3
mdl
MFCD01830853
分子量
221.256
InChiKey
RXKTVGMZJMDNLF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    438.2±45.0 °C(Predicted)
  • 密度:
    1.137

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    47.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:a673d39ce93c61e8d0ed4c86b6b9d54f
查看

上下游信息

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Aminotetralin derivatives
    摘要:
    这项发明涉及公式I的新的氨基四氢萘衍生物,其中B是亚甲基,当A是--CH.sub.2--CH.sub.2--时,B也可以是羰基或硫代羰基;E是一种C.sub.2-C.sub.4直链烷基,可以选择性地被C.sub.1-C.sub.3烷基取代,或者是2-羟基-n-丙烷基,2-羟基-n-丁烷基或3-羟基-n-丁烷基;R.sub.1是氢、氟、氯、溴、三氟甲基、硝基、氨基、C.sub.1-C.sub.3烷基氨基、C.sub.1-C.sub.3二烷基氨基、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷基硫、羟基、C.sub.1-C.sub.3烷氧基或苯基C.sub.1-C.sub.3烷氧基;R.sub.2是氢、氯、溴、羟基、C.sub.1-C.sub.3烷氧基苯基C.sub.1-C.sub.3烷氧基、或C.sub.1-C.sub.3烷基或者与R.sub.1一起可以是C.sub.1-C.sub.2烷二氧基;R.sub.3和R.sub.4各自独立地选自氢、氟、氯、溴、C.sub.1-C.sub.3烷基、羟基、C.sub.1-C.sub.3烷氧基、硝基、氨基、C.sub.1-C.sub.3烷基氨基或C.sub.1-C.sub.3二烷基氨基,或者一起可以是亚甲基二氧基;R.sub.5是氢、C.sub.3-C.sub.5烯丙基、C.sub.1-C.sub.3烷基或苯基C.sub.1-C.sub.3烷基,以及其无毒的、药学上可接受的盐,具有有价值的药理学特性,特别是长效降低心率和减少心脏对O.sub.2需求的作用。
    公开号:
    US04584293A1
  • 作为产物:
    描述:
    6,7-二甲氧基-3,4-二氢异喹啉氢氧化钾三甲基氯硅烷sodiumsilver nitrate 、 sodium iodide 作用下, 以 四氢呋喃甲苯乙腈 为溶剂, 反应 45.5h, 生成 7,8-二甲氧基-1,3,4,5-四氢苯并氮杂卓-2-酮
    参考文献:
    名称:
    Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro- and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti-anginal zatebradine
    摘要:
    The one step AgNO3-mediated ring enlargement of 1-tribromomethyl-1,2-dihydro- and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives into 1,2-dihydro- and 1,2,3,4-tetrahydro-benzo[d]azepin-2-ones, respectively, is reported. This reaction offers a convenient entry to potentially active substances such as the anti-anginal zatebradine. (C) 2003 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0040-4039(03)00919-5
点击查看最新优质反应信息

文献信息

  • 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
    申请人:Peglion Jean-Louis
    公开号:US20090069296A1
    公开(公告)日:2009-03-12
    Compounds of formula (I): wherein: R 1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R 2 , R 3 , R 4 and R 5 each represent a hydrogen atom or a hydroxy, methyl, —OSO 2 R 10 , —OCOR 10 or optionally substituted alkoxy group, or R 2 and R 3 , or R 3 and R 4 , or R 4 and R 5 together form a group —O—(CH 2 ) q —O—, —O—CH═CH—O— or —O—CH═CH—, R 6 , R 7 , R 8 and R 9 each represent a hydrogen atom or an alkoxy group, or R 6 and R 7 , or R 7 and R 8 , or R 8 and R 9 together form a group —O—(CH 2 ) q —O—-, R 10 represents a group selected from linear or branched C 1 -C 6 alkoxy, NR 11 R′ 11 and optionally substituted alkyl, R 11 and R′ 11 each represent a hydrogen atom or an alkyl group, or R 11 and R′ 1 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH 2 , m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers,and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating various pathologies.
    式(I)的化合物: 其中: R1代表氢原子或从环烷基、苄基和可选择地取代的烷基中选择的基团, R2、R3、R4和R5分别代表氢原子或羟基、甲基、—OSO2R10、—OCOR10或可选择地取代的烷氧基,或R2和R3,或R3和R4,或R4和R5一起形成一个基团—O—(CH2)q—O—,—O—CH═CH—O—或—O—CH═CH—, R6、R7、R8和R9分别代表氢原子或烷氧基,或R6和R7,或R7和R8,或R8和R9一起形成一个基团—O—(CH2)q—O—-, R10代表从线性或支链C1-C6烷氧基、NR11R′11和可选择地取代的烷基中选择的基团, R11和R′11分别代表氢原子或烷基基团,或R11和R′1与携带它们的氮原子一起形成一个可选择地取代的、单环或双环、含氮杂环, X代表O、NH或CH2, m和p各自代表0或1, n和q各自代表1或2, 以外消旋形式或光学异构体形式,以及其与药学上可接受的酸的加合盐。 含有这些化合物的药物,对治疗各种病理有用。
  • Cyclic amine derivatives, pharmaceutical compositions containing these
    申请人:Boehringer Ingelheim GmbH
    公开号:US05175157A1
    公开(公告)日:1992-12-29
    Disclosed are new cyclic amine derivatives of the formula I ##STR1## wherein the substituents are defined in the specification. These compounds are useful as for treating sinus tachycardia.
    揭示了新的公式I的环胺衍生物,其中取代基在规范中定义。这些化合物可用于治疗窦性心动过速。
  • (2H)-3-benzazepin-2-ones, their pharmaceutical compositions and their
    申请人:Dr. Karl Tomae, GmbH
    公开号:US04737495A1
    公开(公告)日:1988-04-12
    The invention relates to new heteroaromatic amine derivatives of formula ##STR1## wherein A represents a --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--or ##STR2## group and B represents a methylene, carbonyl or thiocarbonyl group or A represents a --CO--CO or ##STR3## group and B represents a methylene group, in which the carbon atom marked x is linked to the phenyl nucleus, E represents a straight-chained alkylene group optionally substituted by an alkyl group, G represents a straight-chained alkylene group optionally substituted by an alkyl group, R.sub.1 represents a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, nitro, amino, alkylamino, dialkylamino, alkyl, alkylmercapto, hydroxy, alkoxy or phenylalkoxy group, R.sub.2 represents a hydrogen, chlorine or bromine atom or a hydroxy, alkoxy, phenylalkoxy or alkyl group or R.sub.1 and R.sub.2 together represent an alkylenedioxy group, R.sub.3 represents a hydrogen atom, an alkenyl group, an alkyl or phenylalkyl group, and Het represents a 5- or 6-membered heteroaromtic ring bonded via a carbon or nitrogen atom, which contains an oxygen, sulphur or nitrogen atom, two nitrogen atoms or a nitrogen atom and an oxygen or sulphur atom, and onto which additionally a phenyl ring can be condensed, in which case the bond can also be via the phenyl nucleus, or an imidazo[1,2-a]pyridyl group wherein the carbon structure of the above-mentioned groups can be substituted by a methylenedioxy or ethylenedioxy group or can be mono- or disubstituted by a halogen atom or an alkyl, hydroxy, alkoxy, phenylalkoxy, phenyl, dimethoxyphenyl, nitro, amino, acetylamino, carbamoylamino, N-alkyl-carbamoylamino, hydroxymethyl, mercapto, alkylmercapto, alkylsulphinyl, alkylsulphonyl, alkylsulphonyloxy, alkylsulphonylamino, alkoxycarbonylmethoxy, carboxymethoxy or alkoxymethyl group, and at the same time any imino group present in the above-mentioned heteroaromatic groups can be substituted by an alkyl, phenylalkyl or phenyl group, the N-oxides and the acid addition salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly the effect of lowering heart rate and oxygen requirement of the heart. They can be used to treat sinus tachycardia or ischaemic heart disease.
    本发明涉及新的杂芳胺衍生物,其化学式为##STR1##其中A代表--CH.sub.2 --CH.sub.2 --,--CH.dbd.CH--或##STR2##基团,B代表一个亚甲基、羰基或硫代羰基基团,或者A代表--CO--CO或##STR3##基团,B代表一个亚甲基基团,其中标有x的碳原子与苯环相连,E代表一条直链烷基基团,该基团可选择由烷基基团取代,G代表一条直链烷基基团,该基团可选择由烷基基团取代,R.sub.1代表氢、氟、氯或溴原子,三氟甲基、硝基、氨基、烷基氨基、二烷基氨基、烷基、烷基硫醇基、羟基、烷氧基或苯基氧基基团,R.sub.2代表氢、氯或溴原子或羟基、烷氧基、苯基氧基或烷基基团,或者R.sub.1和R.sub.2一起代表烷二氧基基团,R.sub.3代表氢原子、烯基基团、烷基或苯基烷基基团,Het代表通过碳或氮原子键合的含有氧、硫或氮原子、两个氮原子或一个氮原子和一个氧或硫原子的5-或6-成员杂芳环,其上还可以附加一个苯环,并且在这种情况下,键合也可以通过苯环核心进行,或者是一种咪唑并[1,2-a]吡啶基团,在上述基团的碳结构可以被甲二氧基或乙二氧基基团取代,或者可以被卤原子或烷基、羟基、烷氧基、苯基氧基、苯基、二甲氧基苯基、硝基、氨基、乙酰氨基、氨基甲酰氨基、N-烷基-氨基甲酰氨基、羟甲基、硫醇基、烷基硫醇基、烷基磺酰基、烷基磺酰氧基、烷基磺酰氨基、烷氧羰基甲氧基、羧基甲氧基或烷氧甲基基团单取代或双取代,同时上述杂芳基团中存在的任何亚胺基团可以被烷基、苯基烷基或苯基取代,以及它们的N-氧化物和与无机或有机酸形成的酸加合盐,具有有价值的药理性能,特别是降低心率和心脏氧需求的作用。它们可用于治疗窦性心动过速或缺血性心脏病。
  • Benzazepine derivatives, their pharmaceutical compositions and method of
    申请人:Dr. Karl Thomae Gesellschaft mit beschrankter Haftung
    公开号:US04490369A1
    公开(公告)日:1984-12-25
    Compounds of the formula ##STR1## wherein A is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --NH--CO--, --CH.sub.2 --CO-- or ##STR2## where R.sub.7 is alkyl of 1 to 3 carbon atoms, and B is methylene, carbonyl or thiocarbonyl, or A is --CO--CO--, --N.dbd.CH--, ##STR3## where R.sub.8 is hydrogen or alkyl of 1 to 3 carbon atoms substituted by a phenyl, methoxyphenyl or dimethoxyphenyl, and B is methylene; E is n-alkylene of 2 to 4 carbon atoms optionally substituted by an alkyl of 1 to 3 carbon atoms, 2-hydroxy-n-propylene, 2-hydroxy-n-butylene or 3-hydroxy-n-butylene; G is n-alkylene of 1 to 5 carbon atoms optionally substituted by an alkyl of 1 to 3 carbon atoms, wherein one methylene group of an n-alkylene of 2 to 5 carbon atoms can be replaced by a carbonyl group, with the proviso that B represents a methylene or carbonyl group, or methylene-n-hydroxy-alkylene of 1 to 4 carbon atoms, where the methylene group is attached to the nitrogen atom; and R.sub.1 to R.sub.5 are simple substituents of various types; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.
    式为##STR1##的化合物,其中A为--CH.sub.2 --CH.sub.2 --,--CH.dbd.CH--,--NH--CO--,--CH.sub.2 --CO--或##STR2##,其中R.sub.7为1至3个碳原子的烷基,B为亚甲基,羰基或硫代羰基,或A为--CO--CO--,--N.dbd.CH--,##STR3##其中R.sub.8为氢或1至3个碳原子的烷基,其被苯基,甲氧基苯基或二甲氧基苯基取代,B为亚甲基;E为2至4个碳原子的n-烷基,可选择地被1至3个碳原子的烷基,2-羟基-n-丙烯基,2-羟基-n-丁烯基或3-羟基-n-丁烯基取代;G为1至5个碳原子的n-烷基,可选择地被1至3个碳原子的烷基取代,其中2至5个碳原子的n-烷基的一个亚甲基可以被羰基取代,条件是B代表亚甲基或羰基,或者为1至4个碳原子的亚甲基-n-羟基-烷基,其中亚甲基与氮原子相连;R.sub.1至R.sub.5为各种类型的简单取代基;以及其非毒性、药理学上可接受的酸盐。这些化合物及其盐可用作心动过缓药。
  • A ring expansion strategy towards diverse azaheterocycles
    作者:Ruirui Li、Bo Li、Hongpeng Zhang、Cheng-Wei Ju、Ying Qin、Xiao-Song Xue、Dongbing Zhao
    DOI:10.1038/s41557-021-00746-7
    日期:2021.10
    The development of innovative strategies for the synthesis of N-heterocyclic compounds is an important topic in organic synthesis. Ring expansion methods to form large N-heterocycles often involve the cycloaddition of strained aza rings with π bonds. However, in some cases such strategies suffer from some limitations owing to the difficulties in controlling the regioselectivity and the accessibility
    开发合成 N-杂环化合物的创新策略是有机合成中的一个重要课题。形成大 N-杂环的环扩展方法通常涉及具有 π 键的应变氮杂环的环加成。然而,在某些情况下,由于难以控制区域选择性和特定 π 键合成子的可及性,此类策略会受到一些限制。在这里,我们报告了一种通用扩环策略的发展,该策略涉及通过协同双金属催化在三元氮杂杂环与三元环和四元环酮之间进行正式的交叉二聚化。两个不同应变环的这些正式交叉二聚化是高效且可扩展的,并提供了一种直接且广泛适用的组装不同 N-杂环的方法,例如 3-苯并氮杂酮、二氢吡啶酮和尿嘧啶,它们是许多药物和生物活性化合物中的多功能单元。初步的机理研究表明,应变环酮的 C-C 键首先被 Pd 裂解0种在反应过程中。
查看更多